Related Experiment Video
Updated: Jul 13, 2025
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Molecular docking analysis of imiquimod with the TGF-β targets for oral carcinoma
Jayanthi Pazhani1, Vishnu Priya Veeraraghavan1, Selvaraj Jayaraman1
1Centre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600077, India.
Abstract:
TGF-βsignalling pathway is the main signalling pathways that regulate various biological functions such as cell proliferation, apoptosis, metabolic dysregulation, and metastasis in many cancer cells. Previous studies have elaborated the role of TGF-βsignalling targets have a significant regulatory function in various cancers. Moreover targeting the epithelial to mesenchymal transition markers in oral squamous cell carcinoma not yet elucidated. Therefore, it is of interest to document the molecular docking analysis of TGF-βsignalling pathway targets such as Smad2, GATA2 and MAFG with imiquimod. These results suggest that targeting the TGF-βsignaling pathway downstream targets with imiquimod might leads to an improved outcome as potential therapeutic options in oral carcinoma.
Insights
This study explores targeting the transforming growth factor beta (TGF-β) signaling pathway in oral cancer. Molecular docking suggests imiquimod may effectively target key TGF-β pathway proteins, offering potential new therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The transforming growth factor beta (TGF-β) signaling pathway regulates critical cellular processes including proliferation, apoptosis, and metastasis in cancer.
- While TGF-β targets are implicated in various cancers, their role in oral squamous cell carcinoma, particularly epithelial to mesenchymal transition markers, remains underexplored.
Purpose of the Study:
- To investigate the potential of imiquimod as a therapeutic agent against oral carcinoma by examining its interaction with key TGF-β signaling pathway targets.
- To perform molecular docking analysis of imiquimod against Smad2, GATA2, and MAFG, which are downstream targets of the TGF-β pathway.
Main Methods:
- Molecular docking analysis was employed to simulate the binding interactions between imiquimod and selected TGF-β signaling pathway targets (Smad2, GATA2, MAFG).
Main Results:
- The molecular docking analysis revealed potential binding interactions between imiquimod and the TGF-β signaling pathway targets Smad2, GATA2, and MAFG.
- These findings indicate that imiquimod may effectively inhibit the function of these critical downstream targets.
Conclusions:
- Targeting downstream components of the TGF-β signaling pathway, such as Smad2, GATA2, and MAFG, with imiquimod shows promise for oral carcinoma treatment.
- Imiquimod presents a potential therapeutic strategy for oral carcinoma by modulating the TGF-β signaling pathway.
